Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
4.840
-0.120 (-2.42%)
At close: Apr 28, 2026, 4:00 PM EDT
4.800
-0.040 (-0.83%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Niagen Bioscience Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Niagen Bioscience stock have an average target of 16, with a low estimate of 12 and a high estimate of 23. The average target predicts an increase of 230.58% from the current stock price of 4.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Niagen Bioscience stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +168.60% | Mar 31, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +168.60% | Mar 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +189.26% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +147.93% | Aug 11, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $16 | Strong Buy | Maintains | $13 → $16 | +230.58% | Jun 10, 2025 |
Financial Forecast
Revenue This Year
150.79M
from 129.42M
Increased by 16.51%
Revenue Next Year
172.77M
from 150.79M
Increased by 14.58%
EPS This Year
0.28
from 0.20
Increased by 38.98%
EPS Next Year
0.35
from 0.28
Increased by 26.61%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 163.1M | 183.0M | |
| Avg | 150.8M | 172.8M | |
| Low | 141.1M | 159.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 26.0% | 21.3% | |
| Avg | 16.5% | 14.6% | |
| Low | 9.0% | 5.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.35 | 0.39 | |
| Avg | 0.28 | 0.35 | |
| Low | 0.23 | 0.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 73.3% | 39.8% | |
| Avg | 39.0% | 26.6% | |
| Low | 12.7% | 12.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.